24 HR trandolapril 1 MG Verapamil hydrochloride 240 MG Extended Release Oral Tablet

INDICATIONS AND USAGE Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using trandolapril and verapamil hydrochloride extended-release tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS - Neutropenia/Agranulocytosis ).

glenmark pharmaceuticals inc., usa

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] adverse drug reaction` `[3] off label use` `[4] headache` `[5] fatigue` `[6] nausea` `[7] dyspnoea` `[8] pain` `[9] diarrhoea` `[10] application site pruritus`

4 years ago

OVAL WHITE 294

HOW SUPPLIED

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE Extended-Release Tablets, 1 mg/240 mg are supplied as white to pinkish white colored, oval, biconvex, film-coated tablets with ‘294’ debossed on one side and plain on the other side containing 1 mg trandolapril, USP in an immediate-release form and 240 mg verapamil hydrochloride, USP in an extended-release form. NDC 68462-294-90 — bottles of 90 NDC 68462-294-01 — bottles of 100 NDC 68462-294-10 — bottles of 1000

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE Extended-Release Tablets, 2 mg/180 mg are supplied as pink colored, oval, biconvex, film-coated tablets with ‘295’ debossed on one side and plain on the other side containing 2 mg trandolapril, USP in an immediate-release form and 180 mg verapamil hydrochloride, USP in an extended-release form. NDC 68462-295-90 — bottles of 90 NDC 68462-295-01 — bottles of 100 NDC 68462-295-10 — bottles of 1000

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE Extended-Release Tablets, 2 mg/240 mg are supplied as cream colored, oval, biconvex, film-coated tablets with ‘296’ debossed on one side and plain on the other side containing 2 mg trandolapril, USP in an immediate-release form and 240 mg verapamil hydrochloride, USP in an extended-release form. NDC 68462-296-90 — bottles of 90 NDC 68462-296-01 — bottles of 100 NDC 68462-296-10 — bottles of 1000

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE Extended-Release Tablets, 4 mg/240 mg are supplied as brown colored, oval, biconvex, film-coated tablets with ‘G38’ debossed on one side and plain on the other side containing 4 mg trandolapril, USP in an immediate-release form and 240 mg verapamil hydrochloride, USP in an extended-release form. NDC 68462-329-01 — bottles of 100 NDC 68462-329-10 — bottles of 1000 Dispense in well-closed container with safety closure. Storage: Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bardez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com September 2019 logo

More pills like OVAL 294

Related Pills

24 HR trandolapril 2 MG Verapamil hydrochloride 240 MG Extended Release Oral Tablet

glenmark pharmaceuticals inc., usa

24 HR trandolapril 2 MG Verapamil hydrochloride 180 MG Extended Release Oral Tablet

glenmark pharmaceuticals inc., usa

sodium bicarbonate sodium bicarbonate tablet orally disintegrating

rising pharmaceuticals, inc.

oxcarbazepine 600 MG Oral Tablet

American Health Packaging

Indomethacin 50 MG Oral Capsule

Zydus Pharmaceuticals (USA) Inc.

Cephalexin 500 MG Oral Capsule

aidarex pharmaceuticals llc

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site